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Current regimens for the management of human immunodeficiency virus type 1 (HIV-1) infection suppress
plasma viremia to below detectable levels for prolonged intervals. Nevertheless, there is a rapid resumption in
plasma viremia if therapy is interrupted. Attempts to characterize the extent of viral replication under
conditions of potent suppression and undetectable plasma viremia have been hampered by a lack of convenient
assays that can distinguish latent from ongoing viral replication. Using episomal viral cDNA as a surrogate for
ongoing replication, we previously presented evidence that viral replication persists in the majority of infected
individuals with a sustained aviremic status. The labile nature of viral episomes and hence their validity as
surrogate markers of ongoing replication in individuals with long-term-suppressed HIV-1 infection have been
analyzed in short-term in vitro experiments with conflicting results. Since these in vitro experiments do not
shed light on the long-term in vivo dynamics of episomal cDNA or recapitulate the natural targets of infection
in vivo, we have analyzed the dynamics of episomal cDNA turnover in vivo by following the emergence of an
M184V polymorphism in plasma viral RNA, in episomal cDNA, and in proviral DNA in patients on suboptimal
therapies. We demonstrate that during acquisition of drug resistance, wild-type episomal cDNAs are replaced
by M184V-harboring episomes. Importantly, a complete replacement of wild-type episomes with M184V-
containing episomes occurred while proviruses remained wild type. This indicates that episomal cDNAs are
turned over by degradation rather than through death or tissue redistribution of the infected cell itself.
Therefore, evolution of episomal viral cDNAs is a valid surrogate of ongoing viral replication in HIV-1-infected
individuals.
Suppression of plasma viremia to below detectable levels
can be sustained in human immunodeficiency virus type 1
(HIV-1)-infected individuals by antiretroviral regimens cur-
rently in use (14, 30). Nevertheless, replication-competent vi-
ruses persist in these individuals, and viremia rapidly resumes
when antiretroviral suppression is interrupted (10, 13, 16, 28).
Lymphocytes from aviremic patients harbor latent proviruses,
and after in vitro activation, these lymphocytes yield replica-
tion-competent viruses (5, 9, 12, 43). The latent reservoir is
believed to be established early in infection and to constitute
quiescent memory CD4 T lymphocytes harboring transcrip-
tionally silent proviruses (7, 19). The existence of a reservoir of
latently infected cells is considered to be the major obstacle to
eradication of HIV-1 through prolonged antiretroviral sup-
pression (36). This has prompted strategies aimed at triggering
cell cycle progression of latently infected cells and reactivation
of latent proviruses in infected individuals (2, 8, 22, 23, 32).
In addition to a pool of latently infected lymphocytes, there
is evidence that viral persistence in the face of potent antiret-
roviral suppression may be perpetuated by ongoing viral rep-
lication. For example, in patients where drug regimens do not
completely block HIV-1 replication, it has been proposed that
intermittent episodes of plasma viremia may contribute to the
maintenance of the viral reservoir of both latently infected and
productively infected cells (33, 44). Even when plasma viremia
is completely suppressed, continued sequence evolution in the
viral envelope gene, as well as expression of viral RNA in
lymphoid tissues (11, 15, 26, 33, 45), supports the view that
viral replication can persist in the face of potent antiretroviral
suppression. The effectiveness of current therapeutic regimens
has been monitored by using HIV-1 RNA assays which have a
sensitivity to 40 to 50 copies/ml. Below this assay threshold,
more-sensitive assays of HIV-1 RNA reveal that low-level
plasma viremia persists in patients even after years of therapy
(11, 41). While this low-level, steady-state viremia could result
from the continued activation of latently infected cells, its level
can be suppressed by therapy intensification, suggesting that it
is a result of ongoing replication (18). The major contributor to
viral rebound that occurs when therapy is interrupted is also a
matter of debate. In patients with extended periods of unde-
tectable plasma viremia, rebounding virus was genetically sim-
ilar to viruses isolated from the latent reservoir, and in patients
with residual viral replication, the rebound virus corresponded
to minor viral variants detected in lymphoid tissues (44). In
contrast, the rebounding virus in plasma was found to be ge-
* Corresponding author. Mailing address: University of Massachu-
setts, 373 Plantation St., Biotech 2, Suite 319, Worcester, MA 01605.
Phone: (508) 856-4581. Fax: (508) 856-4075. E-mail: mario.stevenson
@umassmed.edu.
5203
 at UNIV O
F M
ASS M
ED SCH on Decem






netically distinct from cell-associated viral RNA and virus re-
covered from resting memory CD4 T cells, suggesting that
the viral rebound was from a source other than the latent
reservoir (6, 20).
Efforts to characterize the extent of ongoing viral replication
in suppressed individuals and the source of the rebounding
virus following interruption of therapy have been hampered by
a lack of convenient surrogates of ongoing viral replication. We
previously provided evidence that viral replication persists in
the majority of aviremic individuals on the basis that episomal
forms of viral cDNA could be detected in these individuals
(35). Viral episomes containing one or two long terminal re-
peats (1- or 2-LTR-containing episomes) are formed after
completion of viral cDNA synthesis and translocation of the
viral genome to the host cell nucleus, where recombination and
direct ligation lead to the formation of episomes containing
one and two LTRs, respectively. In addition, we and others
reported that 2-LTR-containing episomal cDNAs are labile
and, as such, their presence is indicative of recent infection
events (27, 29, 35). However, other studies indicate that epi-
somal viral cDNAs are intrinsically stable in vitro, at least in
experiments extending over a few days (3, 4, 31). Short-term in
vitro studies examining stability of episomal viral cDNA are
limited in their ability to gauge the dynamics of episomal
cDNA in patients who have been aviremic for months to years.
Furthermore, the cell cycle status of the infected cell appears
to impact the stability of extrachromasomal linear viral DNA
(38), and stability of episomal viral cDNA in cell lines and
activated lymphocytes in vitro may not reflect episomal cDNA
dynamics in natural targets of HIV-1 infection in vivo. There-
fore, to gain information on the in vivo dynamics of episomal
viral cDNA, we have monitored the emergence of drug resis-
tance mutations in episomal viral cDNA and in proviral DNA
in patients on suboptimal therapies. We show that episomal
viral cDNAs acquire drug resistance mutations, while provi-
ruses remain wild type. This provides evidence that episomal
viral cDNA is labile in vivo. As such, episomal viral cDNAs are
valid surrogates of ongoing viral replication in HIV-1-infected
individuals.
This study (NWCS225) was conducted using archival patient
samples that had originally been collected under AIDS Clinical
Trials Group protocol no. 306 (24). As part of AIDS Clinical
Trials Group protocol 306, peripheral blood mononuclear cells
were obtained from treatment-naive individuals at various in-
tervals after initiation of dual nucleoside analog therapy. The
presence of drug-resistant viruses in plasma was determined at
week 24 post-therapy initiation. Plasma HIV-1 RNA measure-
ments (branched-DNA assay, HIV-1 quantiplex version 2.0;
Chiron Corp.) was available on most patients for weeks 2, 4, 8,
12, 16, 20, 24, 28, 36, 44, and 48 post-therapy initiation. We
followed the emergence of drug resistance mutations in episo-
mal and proviral DNA in 11 patients who had received zidovu-
dine (ZDV) plus lamivudine (3TC). Under this regimen, re-
sistance to 3TC, which is conferred by a methionine-to-valine
substitution at codon 184 (M184V) of reverse transcriptase
(RT), rapidly develops, such that by week 24 post-therapy
initiation, wild-type HIV-1 in plasma is replaced by 3TC-resis-
tant virus. We developed a PCR strategy which allowed specific
amplification of RT sequences within episomal cDNAs as well
as proviral sequences (Fig. 1). Episomal viral cDNA and pro-
viral DNA were amplified from cellular DNA of archived pe-
ripheral blood mononuclear cells that had been obtained at
various intervals post-therapy initiation (Fig. 1; Table 1). Pro-
viruses were amplified either from total cellular DNA, using an
HIV-1-specific primer and a primer specific for Alu sequences
within chromosomal DNA (21), or from enriched chromo-
somal DNA using HIV-1-specific primers (Fig. 1). Amplifica-
tion of episomal sequences was achieved in two rounds of PCR
amplification. In the first round, sequences encompassing a
portion of Nef, LTR circle junction sequences, Gag, RT, and
integrase were amplified, followed by a second round of nested
PCR using RT-specific primers (Fig. 1; Table 1). In some cases,
2-LTR circles were specifically amplified with a primer which
spans the unique junction formed by ligation of 5 and 3 LTR
sequences in the 2-LTR circle (Fig. 1). Second-round products
were generated in the linear phase of amplification and directly
sequenced. In this amplification strategy, second-round ampli-
cons were not generated if the first-round amplification with
episome-specific primers was omitted. Therefore, the internal
second-round amplicons were derived directly from episomal
sequences rather than from proviral or linear extrachromo-
somal sequences. Where plasma was available, genomic viral
RNA was amplified and genotyped for the presence of the
M184V polymorphism.
The emergence of the M184V polymorphism in episomal (1-
and 2-LTR circles) and proviral DNA for eight patients is
shown on Fig. 2. In each case, plasma viruses obtained around
week 24 post-therapy initiation harbored the M184V polymor-
phism. In four cases (038, 169, 268, and 270) where plasma was
available from earlier intervals, the M184V mutation was de-
tected in genomic plasma viral RNA by 8 weeks post-therapy
initiation. Despite the emergence of viruses harboring 3TC
resistance mutations, viral load remained suppressed, most
likely through the presence of ZDV. While the M184V muta-
tion confers 3TC resistance, it restores ZDV susceptibility in
HIV-1 variants carrying ZDV resistance mutations, and ZDV
resistance mutations are less frequent in viruses from patients
receiving ZCV plus 3TC than in those from patients receiving
ZDV monotherapy (25, 40). Previous studies have demonstrated
that the majority of patients on ZDV-3TC combinations de-
velop M184V mutations by 12 weeks post-therapy initiation
(25), which illustrates the rapid replacement of wild-type vi-
ruses by drug-resistant variants under suboptimal therapies.
In most subjects (038, 073, 115, 169, 179, 268, 270, and 278),
wild-type episomes were replaced by episomes containing the
M184V mutation by 24 weeks post-therapy initiation. In three
cases, the population of wild-type episomes had been com-
pletely (179 and 270) or partially (278) replaced by drug-resis-
tant episomes by 12 weeks post-therapy initiation. Importantly,
there was no corresponding appearance of the M184V muta-
tion in the proviral species in these patients over 48 weeks
post-therapy initiation (Fig. 2). Only in one subject (169) were
M184V-containing proviruses evident, and only at the last two
intervals post-therapy initiation.
In three patients (013, 230, and 289), the appearance of the
M184V polymorphism in episomal DNA was delayed relative
to the case with the other patients, and proviral DNA re-
mained wild type (Fig. 3). One possibility is that the level of
ongoing replication in these three patients was lower. In this
case, the replacement of wild-type episomes by de novo-syn-
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thesized M184V-episomes would be delayed. To evaluate
whether the level of ongoing replication was lower in patients
exhibiting a slow evolution to M184V episomes, we compared
the genetic divergence in viral envelope sequences in 2-LTR
episomal DNA from week 0 to week 24 and from week 24 to
week 48 in two patients (179 and 270) where there was a rapid
evolution in episomal sequences and two patients (230 and
289) where there was a delay in the appearance of M184V
episomes. Six unique nucleotide sequences spanning the C2
and V3 coding regions of the envelope gene isolated from
episomal cDNA at weeks 0, 24, and 48 were determined. To
specifically amplify envelope sequences from 2-LTR circle ge-
nomes, primers LA9 and BB were used for eight cycles of
first-round PCR specifically targeting 2-LTR circle templates
(Table 1). Ten percent of primary products were amplified for
10 cycles using 2-LTR circle-specific nested primers LA1 and
LA10. The secondary products were serially diluted to deter-
mine PCR endpoints, and replicate amplifications using prim-
ers LA11 and Env6 were used to generate products that were
used directly for sequencing. Nucleotide sequences corre-
sponding to the C2 and V3 regions of Env were aligned using
ClustalW (MacVector 7.1.1.), and phylogenetic relationships
were generated by using the neighbor-joining method included
in the MacVector software package with a Kimura-2 parame-
ters distance matrix. Confidence limits for individual branches
were estimated by bootstrap resampling of the neighbor-join-
ing trees (1,000 replicates). Phylogenetic analysis of these se-
quences revealed clusters of viral sequences for each patient
FIG. 1. Strategy for long-range PCR amplification of episomal HIV-1 cDNAs containing RT or envelope sequences. Major cDNA interme-
diates in reverse transcription are denoted. Thin line, viral RNA; thick line, cDNA. Primer-binding sites for initiation of minus-strand cDNA
synthesis and polypurine tracks for plus- or minus-strand synthesis are indicated by open circles and squares, respectively. First-, second-, and
third-round primer sets are indicated next to the specific cDNA intermediate they are designed to amplify. HIV-1 pol sequences were amplified
using Jumpstart REDAccuTaq DNA polymerase (Sigma), following the manufacturer’s protocol with the following modifications. Amplifications
were done in a 50-l reaction mixture containing 1 buffer, 0.5 mM deoxynucleoside triphosphates, 0.5 M primers, 1.5 U of REDAccuTaq, and
10 l (10% of total) of either episomal or chromosomal DNA purified from patient peripheral blood lympocytes. After an initial denaturation at
94°C for 2 min, first-round products were generated by cycling 25 to 30 times at 94°C for 15 s, 60°C for 30 s, and 68°C for 1 min per kilobase pair
of target sequence. The first-round extension time for Alu PCR was 5 min. One or two microliters from the first round was then subjected to 20
to 30 cycles of amplification under the same reaction conditions.
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that were distinct from each other (Fig. 4) and from HIV
clones commonly used in the laboratory (data not shown).
Individual phylogenetic trees revealed that genetic distances
from week 0 to week 24 and from week 24 to week 48 were
greater in patients 179 and 270, where there was rapid evolu-
tion of M184V-containing episomes, than in patients 230 and
289, where the conversion was delayed (Fig. 4; Table 2). This
suggests that the delayed appearance of M184V-containing
FIG. 2. Evolution of codon 184 of HIV-1 RT in episomal and proviral cDNAs in patients on ZDV-3TC therapy. For each patient, plasma viral
RNA loads were monitored after the initiation (week 0) of dual therapy. In each case, an M-to-V substitution at codon 184, which confers
resistance to 3TC, was evident at week 24 post-therapy initiation. At various intervals following initiation of ZDV-3TC therapy, the amino acid
identity for codon 184 was determined in plasma viral RNA, episomal DNA, and proviral DNA. Boxes indicate the sampling intervals. A solid box
denotes the exclusive presence of the M184V mutation in sequence electropherograms of PCR products at that sampling interval. Partially filled
boxes denote the presence of both wild-type and M184V genotypes at that sampling interval.
TABLE 1. Primers used for long range amplification of episomal and proviral sequences encompassing RT or envelopea
Amplicon Sequence(s)encompassed Substrate Primers
Amplification
round
Episome (1-  2-LTR circle) LTR, Gag, Pol, Env Extrachromosomal DNA LA3  LA7 1
DR pol f  Dr pol r 2
2-LTR circle LTR, Gag, Pol, Env Extrachromosomal DNA Jct f  LA7 1
DR pol f  Dr pol r 2
Provirus Pol Chromosomal DNA LA2  LA7 1
LA5  LA6 2
Provirus LTR, Gag, Pol Chromosomal DNA Alu f  LA7 1
DR pol f  DR pol r 2
2-LTR circle LTR, Env Extrachromosomal DNA LA9  BB 1
LA1  LA10 2
LA11  Env 6 3
a Primers are numbered according to the HIV-1LAI consensus (K02013). LA1, 5-G260CGCTTCAGCAAGCCGAGTCCT; LA2, 5-C1785CCTCTCAGAAGCAG
GAGCCGA; LA3, 5-T8386AAGATGGGTGGCAAGTGGTCA; LA5, 5-G1907ATACAGGAGCAGATGATACA; LA6, 5-C3761TCCAATTCCTTTGTGTGCTG;
LA7, 5-T3975CTACTTGTCCATGCATGGCTT; LA9, 5-A6015CATGCCTGTGTACCCACAGA; LA10, 5-C6428CTGTCCAAAGGTATCCTTTGA; LA11, 5-C6546
ACAGTACAATGTACACATGGA; Alu f, 5-CTCACGCCTGTAATCCCAGCA; Jct f, 5-AATCTCTAGCAGTACTGGAAG (spans circle junction); BB, 5-G478
GATTAACTGCGAATCGTTC; Env6, 5-T8179GCGTCCCAGAAGTTCCACAA; DR pol f, 5-T2064AGGACCTACACCTGTCAACATAA; DR pol r, 5-C2908TTC
TGTATGTCATTGACAGTCCA.
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episomes in patients 230 and 289 was due to lower levels of
ongoing replication and hence slower replacement of wild-type
episomes with M184V-containing episomes.
Because of incomplete viral suppression and rapid clearance
of virions (30), wild-type viruses in plasma are rapidly replaced
by drug-resistant variants within weeks of initiating suboptimal
therapy. In this study, we tracked the emergence of drug re-
sistance mutations in episomal and proviral DNA in patients
on such suboptimal therapies. We demonstrate that in most
cases, the wild-type episomal cDNA population is replenished
by a drug-resistant episomal population even though provi-
ruses remain wild type. One possible explanation is that epi-
somes are labile and, during ongoing replication, episomes
decay and are replaced as a result of ongoing infection. An
alternative explanation is that episomes are intrinsically stable.
In the latter scenario, the replacement of wild-type episomes
with drug-resistant episomes could be explained by turnover of
episome-harboring cells or their redistribution to tissue com-
partments. We feel this explanation is unlikely, since one
would expect a similar evolution of drug resistance mutations
in the proviral species. Our finding that drug resistance muta-
tions evolve in episomes but not proviruses strongly argues for
an intrinsic instability of episomal cDNAs rather than death or
redistribution of the infected cell itself. As episomes are syn-
thesized and degraded, they are replenished by episomes syn-
thesized de novo during ongoing viral replication. In patients
where there was a delay in the appearance of M184V epi-
somes, we also documented significantly lower rates of genetic
divergence. Therefore, the rate with which the episomal cDNA
pool evolves can be expected to vary between patients depend-
ing upon the ongoing level of viral replication. Because anti-
retroviral therapy impacts selection pressure, evolution rate
cannot be a direct measure of replication. Nevertheless, the
evolution of episomal cDNA can be used to determine relative
levels of viral replication in patients on similar regimens. We
feel that lower levels of ongoing viral replication provide a
better explanation for the slower conversion to M184V epi-
somes observed in three patients than intrinsic differences in
stability of episomal cDNA in different cell types. Viral repli-
cation has been documented in both resting and activated
CD4 T cells (46). While we cannot rule out the possibility
that episomal cDNA stability may be influenced by cell cycle
status, we feel it unlikely that significant differences in the
distribution of episomal cDNA in resting and activated CD4
T cells would explain the markedly different rates with which
M184V episomes emerged in the patients studied here.
Our observation that wild-type proviruses are maintained,
despite the emergence of drug resistance mutations in plasma
FIG. 3. Delayed emergence of M184V mutations in episomal cDNA in patients on dual nucleoside therapy. Symbols are as described in the
legend for Fig. 2.
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viral RNA and in episomal cDNA, is not unexpected. Previous
studies examining total cell-associated viral DNA have shown
that viral DNA levels decay slowly and emergence of drug
resistance mutations is greatly delayed relative to results with
plasma viral RNA (1, 17, 34, 37, 42). In one study, emergence
of the M184V mutation was compared in genomic viral RNA
and viral DNA; however, there was no attempt to distinguish
the emergence of the mutations in the different species of viral
DNA (37). To our knowledge, this is the first study to inde-
pendently characterize the emergence of drug resistance mu-
tations in proviral and in episomal cDNA. Our results would
suggest that during ongoing viral replication, only a small per-
centage of the proviruses are a result of recent infection events,
and that the majority of proviruses are nondynamic and are
archival because they are either defective or latent. By com-
parison, our data provide evidence that episomal cDNAs are
labile and, as such, are surrogates of ongoing viral replication.
The ability to monitor the extent of HIV-1 replication in
aviremic patients on suppressive therapies has been hampered
FIG. 4. Phylogenetic relationships in episomal (2-LTR circle) envelope genes in patients with rapid and delayed evolution of M184V
polymorphisms in episomal cDNA. Nested PCR was used to specifically amplify envelope sequences from 2-LTR circles, using primers detailed
in Table 1. Nucleotide sequences corresponding to the C2 and V3 regions of the envelope glycoprotein were aligned by using Clustal W
(MacVector 7.1.1), and the phylogenetic relationships were generated by using the neighbor joining method included in the Mac Vector software
package with a Kimura-2 parameters distance matrix. Six unique nucleotide sequences spanning C2 and V3 were determined at weeks 0 (circles),
24 (squares), and 48 (triangles) of the study for two patients (179 and 270) with rapid emergence of M184V episomes and two patients (230 and
289) with delayed emergence of the M184V polymorphism in episomal cDNA. Median genetic distances for early and late converters were
significantly different (P  0.03) in a Mann-Whitney nonparametric analysis.








Patient 230 289 179 270
Weeks 0–24 0.020 0.013 0.052 0.085
Weeks 24–48 0.045 0.039 0.081 0.184
a Kimura-2 parameters distance, taking into account the sum of transitions and
transversions, with a ratio of transitions to transversions of 1.
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by a lack of convenient markers of ongoing viral replication.
The validity of episomal cDNAs as surrogates of ongoing viral
replication has been questioned by studies demonstrating in-
trinsic stability of episomal cDNA in short-term in vitro exper-
iments (4, 31). In one study, in experiments extending over 10
days, the authors reported a decay in 2-LTR circles and con-
cluded that the decay was a result of dilution through cell
division rather than degradation of episomal DNA (31). In
another study, no significant decay in 2-LTR circle forms in a
CD4-T-cell line was noted over a 70-h time period under
single-cycle infection conditions (4). In contrast, other studies
have shown that episomal viral cDNA is labile in primary cells
and CD4-T-cell lines (29, 35, 39) and in vivo (27, 35). Re-
gardless of the differences in these studies, the in vitro exper-
iments are limited in that they track circle stability in experi-
ments extending over a period of days. In patients on highly
active antiretroviral regimens, plasma viral RNA is suppressed
to below the level of detection for months to years. Therefore,
short-term in vitro studies on episomal DNA stability do not
provide an accurate assessment of the dynamics of episomal
viral cDNA turnover in patients on long-term suppressive ther-
apies. Our data provide direct evidence for the in vivo evolu-
tion and turnover of episomal viral cDNA. As such, we feel it
is unlikely that episomes detected in patients on highly sup-
pressive therapies, who have been aviremic for extended inter-
vals, are archival and were originally formed during the viremic
phases of the patient’s infection history. Monitoring levels of
episomal DNA or cDNAs offers one approach for gauging the
level of ongoing viral replication in these individuals. Our data
argue that the ability to detect episomal viral cDNA in avire-
mic patients on highly suppressive therapies (35) provides ev-
idence of ongoing viral replication in these individuals.
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